Nexium IV

See also: Generic Nexium

Nexium IV is a brand name of esomeprazole, approved by the FDA in the following formulation(s):

NEXIUM IV (esomeprazole sodium - injectable; intravenous)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: March 31, 2005
  
  Strength(s): EQ 20MG BASE/VIAL ^[RLD], EQ 40MG BASE/VIAL ^[RLD]

Has a generic version of Nexium IV been approved?

No. There is currently no therapeutically equivalent version of Nexium IV available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexium IV. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
  Patent 5,877,192
  Issued: March 2, 1999
  Inventor(s): Lindberg; Per & Weidolf; Lars
  Assignee(s): Astra Aktiebolag
  A method for treatment of gastric acid related diseases by inhibition of gastric acid secretion comprising administering to a mammal in need of treatment a therapeutically effective amount of the (-)-enantiomer of 5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H-benz imidazole or a pharmaceutically acceptable salt thereof, so as to effect decreased interindividual variation in plasma levels upon administration. The use of the (-)-enantiomer of omeprazole to receive increased average plasma levels (AUC) upon administration of the same doses of the (-)-enantiomer of omeprazole compared to those of racemic omeprazole is also claimed, as well as an improved antisecretory effect and a better clinical effect.
  
  Patent expiration dates:
  
  
  • May 27, 2014
    
    ✓ 
    Patent use: THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
  
  
  
  • November 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Compounds
  Patent 6,143,771
  Issued: November 7, 2000
  Inventor(s): Lindberg; Per Lennart & von Unge; Sverker
  Assignee(s): AstraZeneca AB
  The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
  
  Patent expiration dates:
  
  
  • May 27, 2014
    
    ✓ 
    Patent use: THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
    ✓ 
    Drug product
  
  

See also...

• Nexium I.V. Consumer Information (Drugs.com)
• Nexium I.V. Consumer Information (Wolters Kluwer)
• Nexium I.V. Advanced Consumer Information (Micromedex)
• Esomeprazole Consumer Information (Wolters Kluwer)
• Esomeprazole Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Esomeprazole Delayed-Release Oral Suspension Consumer Information (Wolters Kluwer)
• Esomeprazole Consumer Information (Cerner Multum)
• Esomeprazole Advanced Consumer Information (Micromedex)
• Esomeprazole Oral, Intravenous Advanced Consumer Information (Micromedex)
• Esomeprazole Magnesium AHFS DI Monographs (ASHP)
• Esomeprazole Sodium AHFS DI Monographs (ASHP)